跳至主要内容
临床试验/NCT02970799
NCT02970799已完成不适用

Randomized, Controlled, Crossover Study Comparing Tear Production by Nasal Neurostimulation Versus Active Control

Oculeve, Inc.0 个研究点目标入组 27 人开始时间: 2016年8月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Oculeve, Inc.
入组人数
27
主要终点
Acute Tear Production by Jones Schirmer Test

研究概览

简要总结

This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.

详细描述

In this randomized, controlled study, participants will receive two applications of approximately a three-minute duration, one intranasal (active) and one extranasal (control), in randomized sequence at Visit 2 (Day 1). At Visits 3 (Day 15) and 4 (Day 29), participants will undergo two applications of approximately an eight-minute duration, one intranasal (active) and one extranasal (control), in randomized sequence. The Schirmer test is a clinically relevant and accepted measure to assess tear production over a specified time interval, generally five minutes. Tear meniscus height (TMH) and, to a lesser extent, tear meniscus area (TMA) have been reported as measures of tear quantity and/or production and have been used to diagnose dry eye disease (DED). One reliable means of measuring TMH and TMA is via use of optical coherence tomography (OCT), an established medical imaging technique that uses light to capture micrometer-resolution images from within optical scattering media such as biological tissue. Due to the non-invasive nature of the technique, this study was designed to explore the utility of TMH and TMA captured by OCT as a means of evaluating stimulated tear production following use of the study device.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mild to severe dry eye disease
  • Have not worn contact lenses for at least seven days prior to the Screening Visit and willing to forego the use of contact lenses for the duration of the study
  • Literate, able to speak English or Spanish, and able to complete questionnaires independently

排除标准

  • Previously used the Intranasal Neurostimulator at any time
  • Used commercial lid hygiene product within 14 days of the Screening Visit or plan to use at any time during the study
  • Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the investigator, may lead to the risk of clinically significant increased bleeding
  • Nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
  • Severe nasal airway obstruction (e.g. severe septal deviation or inferior turbinate hypertrophy) or vascularized polyp as confirmed by nasal endoscopic examination at the Screening Visit
  • Have an implanted metallic or other electronic device in the head, a cardiac demand pacemaker, or an implanted defibrillator
  • Participation in any clinical trial with a new active substance or a new device within 30 days of the Screening Visit

结局指标

主要结局

Acute Tear Production by Jones Schirmer Test

时间窗: Day 1

次要结局

未报告次要终点

研究者

发起方
Oculeve, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验

Tear Production by Nasal Neurostimulation Compared... | 临床试验